Published in Clin Cancer Res on June 10, 2014
Human Schlafen 5 (SLFN5) Is a Regulator of Motility and Invasiveness of Renal Cell Carcinoma Cells. Mol Cell Biol (2015) 1.42
Prognostic significance of promoter CpG island methylation of obesity-related genes in patients with nonmetastatic renal cell carcinoma. Cancer (2017) 1.38
Role of DNA methylation in renal cell carcinoma. J Hematol Oncol (2015) 1.02
DACH1 inhibits cyclin D1 expression, cellular proliferation and tumor growth of renal cancer cells. J Hematol Oncol (2014) 0.96
Epigenomics of clear cell renal cell carcinoma: mechanisms and potential use in molecular pathology. Chin J Cancer Res (2016) 0.91
Post-conversion targeted capture of modified cytosines in mammalian and plant genomes. Nucleic Acids Res (2015) 0.89
Genome-wide assays that identify and quantify modified cytosines in human disease studies. Epigenetics Chromatin (2015) 0.88
The epigenetic landscape of renal cancer. Nat Rev Nephrol (2016) 0.81
Interindividual epigenetic variation in ABCB1 promoter and its relationship with ABCB1 expression and function in healthy Chinese subjects. Br J Clin Pharmacol (2015) 0.77
Inactivation of bone morphogenetic protein 2 may predict clinical outcome and poor overall survival for renal cell carcinoma through epigenetic pathways. Oncotarget (2015) 0.77
Notch pathway is activated via genetic and epigenetic alterations and is a therapeutic target in clear cell renal cancer. J Biol Chem (2016) 0.75
Prognostic value of cross-omics screening for kidney clear cell renal cancer survival. Biol Direct (2016) 0.75
A pre-neoplastic epigenetic field defect in HCV-infected liver at transcription factor binding sites and polycomb targets. Oncogene (2016) 0.75
Epigenetic therapy in urologic cancers: an update on clinical trials. Oncotarget (2016) 0.75
CYP1B1 promotes tumorigenesis via altered expression of CDC20 and DAPK1 genes in renal cell carcinoma. BMC Cancer (2015) 0.75
Methylation and expression of PTPN22 in esophageal squamous cell carcinoma. Oncotarget (2016) 0.75
Upregulation of TET activity with ascorbic acid induces epigenetic modulation of lymphoma cells. Blood Cancer J (2017) 0.75
Link between dysregulated hypoxia signaling and aberrant methylation in clear cell renal cell carcinoma? Chin J Cancer Res (2017) 0.75
DNMT1-maintained hypermethylation of Krüppel-like factor 5 involves in the progression of clear cell renal cell carcinoma. Cell Death Dis (2017) 0.75
Gene ontology: tool for the unification of biology. The Gene Ontology Consortium. Nat Genet (2000) 336.52
The fundamental role of epigenetic events in cancer. Nat Rev Genet (2002) 30.05
Mapping and analysis of chromatin state dynamics in nine human cell types. Nature (2011) 24.37
The human colon cancer methylome shows similar hypo- and hypermethylation at conserved tissue-specific CpG island shores. Nat Genet (2009) 18.90
Comprehensive molecular characterization of clear cell renal cell carcinoma. Nature (2013) 13.60
Exome sequencing identifies frequent mutation of the SWI/SNF complex gene PBRM1 in renal carcinoma. Nature (2011) 13.30
Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol (2009) 12.41
Targeted and genome-scale strategies reveal gene-body methylation signatures in human cells. Nat Biotechnol (2009) 11.18
Renal-cell carcinoma. N Engl J Med (2005) 10.17
Selective inhibition of tumor oncogenes by disruption of super-enhancers. Cell (2013) 8.37
ChromHMM: automating chromatin-state discovery and characterization. Nat Methods (2012) 7.66
DNA methylation in cancer: too much, but also too little. Oncogene (2002) 6.96
DNA methylation signatures identify biologically distinct subtypes in acute myeloid leukemia. Cancer Cell (2010) 6.72
Notch signaling controls multiple steps of pancreatic differentiation. Proc Natl Acad Sci U S A (2003) 6.55
Comparative isoschizomer profiling of cytosine methylation: the HELP assay. Genome Res (2006) 5.99
HIF-alpha effects on c-Myc distinguish two subtypes of sporadic VHL-deficient clear cell renal carcinoma. Cancer Cell (2008) 4.84
CEAS: cis-regulatory element annotation system. Bioinformatics (2009) 4.26
Transcriptome analysis of human diabetic kidney disease. Diabetes (2011) 2.32
Derepression of an endogenous long terminal repeat activates the CSF1R proto-oncogene in human lymphoma. Nat Med (2010) 1.93
High-resolution genome-wide cytosine methylation profiling with simultaneous copy number analysis and optimization for limited cell numbers. Nucleic Acids Res (2009) 1.80
An integrative genomic and epigenomic approach for the study of transcriptional regulation. PLoS One (2008) 1.76
Genome-wide epigenetic analysis delineates a biologically distinct immature acute leukemia with myeloid/T-lymphoid features. Blood (2009) 1.75
Genome-wide methylation analysis identifies epigenetically inactivated candidate tumour suppressor genes in renal cell carcinoma. Oncogene (2010) 1.69
Cancer epigenetics: DNA methylation and chromatin alterations in human cancer. Adv Exp Med Biol (2003) 1.65
An analytical pipeline for genomic representations used for cytosine methylation studies. Bioinformatics (2008) 1.64
A distal single nucleotide polymorphism alters long-range regulation of the PU.1 gene in acute myeloid leukemia. J Clin Invest (2007) 1.63
Pathobiology, prognosis, and targeted therapy for renal cell carcinoma: exploiting the hypoxia-induced pathway. Clin Cancer Res (2003) 1.57
Genetics and epigenetics of renal cell cancer. Biochim Biophys Acta (2007) 1.56
Identification of candidate tumour suppressor genes frequently methylated in renal cell carcinoma. Oncogene (2010) 1.52
Aberration in DNA methylation in B-cell lymphomas has a complex origin and increases with disease severity. PLoS Genet (2013) 1.50
Widespread hypomethylation occurs early and synergizes with gene amplification during esophageal carcinogenesis. PLoS Genet (2011) 1.47
Wilms tumor chromatin profiles highlight stem cell properties and a renal developmental network. Cell Stem Cell (2010) 1.34
Sunitinib and other targeted therapies for renal cell carcinoma. Br J Cancer (2011) 1.27
VHL gene mutations in renal cell carcinoma: role as a biomarker of disease outcome and drug efficacy. Curr Oncol Rep (2009) 1.25
Genetic and epigenetic alterations during renal carcinogenesis. Int J Clin Exp Pathol (2010) 1.11
Gene expression profiles of tumor biology provide a novel approach to prognosis and may guide the selection of therapeutic targets in multiple myeloma. J Clin Oncol (2009) 1.09
Transforming growth factor-β, bioenergetics, and mitochondria in renal disease. Semin Nephrol (2012) 1.09
Late-replicating heterochromatin is characterized by decreased cytosine methylation in the human genome. Genome Res (2011) 0.99
Global histone acetylation levels: prognostic relevance in patients with renal cell carcinoma. Cancer Sci (2010) 0.97
Noncytotoxic differentiation treatment of renal cell cancer. Cancer Res (2011) 0.94
Prognostic role of global DNA-methylation and histone acetylation in pT1a clear cell renal carcinoma in partial nephrectomy specimens. J Cell Mol Med (2008) 0.91
Decreased acetylation of histone H3 in renal cell carcinoma: a potential target of histone deacetylase inhibitors. J Urol (2008) 0.90